Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.
Type:
Grant
Filed:
September 23, 2011
Date of Patent:
October 28, 2014
Assignee:
Biogen Idec MA Inc.
Inventors:
Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
Type:
Application
Filed:
June 17, 2014
Publication date:
October 16, 2014
Applicant:
BIOGEN IDEC MA INC.
Inventors:
Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Ma Bin, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
Abstract: The present invention provides a formulation of a Factor VIII polypeptide, e.g., FVIII-Fc, and methods of using the same. The FVIII polypeptide can be a recombinant FVIII protein, a short-acting FVIII protein, or a long-acting FVIII protein. The pharmaceutical formulation comprising a FVIII polypeptide can be used for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of hemophilia.
Type:
Application
Filed:
March 14, 2014
Publication date:
October 16, 2014
Applicant:
Biogen Idec MA Inc.
Inventors:
Kevin MALONEY, Daniel Gage, Ahmad Abdul-Fattah
Abstract: Provided are pro-coagulant compounds (e.g., pro-coagulant peptides or peptide derivatives) and methods of using and making those compounds. Further provided are conjugates between a pro-coagulant compound of the present disclosure (e.g., pro-coagulant peptide or peptide derivative) and a polypeptide selected from FIX, FVIIa, FVIII, and platelet targeting moieties (e.g., PDG-13), wherein the compound is linked to the polypeptide optionally via a linker. The compounds and conjugates are useful for the treatment of coagulation disorders, such as hemophilia A and hemophilia B. Further provided are methods of using and making the conjugates.
Type:
Application
Filed:
June 9, 2012
Publication date:
October 9, 2014
Applicant:
Biogen IDEC MA Inc.
Inventors:
Karina Thorn, Garabet G. Toby, Adam R. Mezo
Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.
Type:
Application
Filed:
January 22, 2014
Publication date:
October 2, 2014
Applicant:
BIOGEN IDEC MA INC.
Inventors:
Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W.T. Van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.
Abstract: Aspects of the invention are directed to arginine-free polypeptide-containing compositions and methods for treating disorders associated with inflammation or the autoimmune response. In particular, the polypeptide is etanercept.
Abstract: In one aspect, the disclosure provides methods for isolating nucleic acid from a Cerebrospinal Fluid (CSF) sample. In one aspect, the disclosure provides methods for determining the amount of JC virus DNA in a sample.
Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
Abstract: Therapeutic regimens for administration of BAFF antagonists for treatment of immunologic and related disorders are described. Regimens involve a short-term BAFF antagonist administration course followed by an extended no-treatment period prior the round of administration.
Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.
Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
Type:
Grant
Filed:
November 14, 2012
Date of Patent:
August 26, 2014
Assignee:
Biogen Idec MA Inc.
Inventors:
David J. Burke, Shaun E. Buckley, Sherwood Russ Lehrman, Barbara Horsey O'Connor, James Callaway, Christopher P. Phillips
Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain integrin antagonists.
Type:
Application
Filed:
January 17, 2014
Publication date:
August 21, 2014
Applicants:
Imperial College of Science, Technology and Medicine, Biogen Idec MA Inc.
Abstract: The invention relates to methods for producing mammalian cells having enhanced characteristics such as faster growth rates and the ability to grow to higher cell densities. The invention also relates to methods for producing cells having the ability to grow in media lacking components such as insulin and insulin substitutes. The invention also relates to isolated mammalian cells having improved growth characteristics and/or the ability to grow in media lacking components such as insulin and insulin substitutes.
Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.
Type:
Application
Filed:
January 2, 2014
Publication date:
August 14, 2014
Applicant:
Biogen Idec MA Inc.
Inventors:
Daniel H.S. Lee, Dingyi Wen, R. Blake Pepinsky, Jane K. Relton, Xinzhong Wang, Alexey Lugovskoy, Werner Meier, Ellen A. Garber, Laura Silvian, Paul H. Weinreb
Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
Type:
Grant
Filed:
August 5, 2010
Date of Patent:
August 12, 2014
Assignee:
Biogen Idec MA Inc.
Inventors:
Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
Abstract: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.
Type:
Application
Filed:
December 19, 2013
Publication date:
August 7, 2014
Applicant:
BIOGEN IDEC MA INC.
Inventors:
Herman Van Vlijmen, Alexey Alexandrovic Lugovskoy, Karl J.M. Hanf
Abstract: A tool for aiding a user author labels for drugs. The tool receives inputs that define requirements for a label, or aggregated requirements for a set of related labels. The requirements may be derived from inputs specifying values of label attributes and then be used to identify fields to appear in each of one or more labels to be generated. Information on fields may be used to dynamically render an interface through which a user may specify text strings to appear in each field when label text is generated. Input elements of the interface may be populated with lists of options identified based on the requirements. The requirements may also be used in generating similar labels and assessing the impact of changes, such as to regulatory requirements. The tool may be particularly useful for authoring labels for clinical trials in which multiple label formats for multiple countries may be generated.
Type:
Application
Filed:
June 29, 2012
Publication date:
August 7, 2014
Applicant:
Biogen Idec MA Inc.
Inventors:
Christine P. Janson, Ethan B. Jacoby, Jeffrey Cooper